



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Proficiency testing for veterinary laboratories

Histopathology and immunohistochemistry interpretation (PT II 24)

Distribution date: October 2024

General comments

The TSE interpretation EQA is an exercise that allows all the NRLs to demonstrate their competence at reading stained/immunolabelled slides as part of their TSE diagnostic capability.

Attached below you will find a table summarising the results of the 2024 EQA round in conjunction with each participant ID.

The use of inconclusive/unsuitable for a case in which a definitive diagnosis is considered possible is not an 'incorrect' result in this context. A negative case called positive, or a positive case interpreted as negative are the only results which are considered 'incorrect'.

Correct and 'Safe' results are highlighted **green**. 'Incorrect' results are highlighted in **red**. Inconclusive or unsuitable returns are highlighted in **yellow**.

In the scrapie IHC category, readers were also invited to comment on whether the case is classical or atypical. Where a case is correctly diagnosed as positive, but subsequently misclassified, this has been identified on the table by highlighting the fonts of either "Pos-A" or "Pos-C" in **pink**.

You should each have received email notification of your unique 'ObserverID'. You will need this to identify your results in the table. Please keep this information safely – your ID will NOT change with subsequent rounds. If you have misplaced your ID then please contact Dr Giuseppe Ru (giuseppe.ru@izsto.it) directly, and the information will be re-sent. If you know of new staff who require to be added to the programme, or existing members of staff who no longer need to participate in this EQA then please contact us.

It is important to review any cases for which you have given an incorrect answer (highlighted in **red and **pink**) and fill the 'Slide review form' (at the end of this document) and return it to Giuseppe Ru (giuseppe.ru@izsto.it) and a copy to Barbara Iulini (barbara.iulini@izsto.it).**

Please use one form for each misclassified case.

This confirms for the EURL (and your own third party quality systems) that appropriate follow-on review of sections has taken place with those readers who require to re-read particular slides.



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino


Istituto Superiore di Sanità – Roma

Comments on the results

The summary table below has grouped the cases according to species so if you wish to refer back to a particular case, please check the case number carefully at the top of the table.

Thank you.

Date:

Barbara Iulini.....
Referent for Confirmatory Histopathology and Immunohistochemistry tests
Veterinary pathologist of Neuropathology Laboratory at IZSPLVA Italy

Giuseppe Ru.....
Director of TSE EURL

Table 1. Results submitted by the participants in the PT II 24

Case number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Test Type	IHC	IHC	H&E	IHC	IHC	IHC	H&E	IHC	IHC	H&E	IHC	H&E	IHC	IHC	IHC
Gold standard result	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
	Bov	Ov	Ov	Ov	Ov	Ov	Bov	Ov	Ov	Ov	Ov	Bov	Bov	Ov	Ov
Species															
IHC result of all H&E sections															
User ID															
84	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
99	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
126	Pos	Inc	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Pos	Pos-C	Pos-A
140	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
162	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
168	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
172	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
184	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Inc	Pos-C	Neg	Neg	Pos-C	Pos-A
227	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
232	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
261	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
265	Pos	Inc	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
288	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
307	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Inc	Neg	Pos-C	Pos-A
340	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
346	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Inc	Pos-C	Pos-A
364	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
386	Pos	Uns	Pos	Pos-C	Uns	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
393	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
403	Pos	Inc	Pos	Pos-C	Inc	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
494	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Inc	Pos-C	Pos-A
530	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Inc	Pos-C	Neg	Neg	Pos-C	Pos-A
546	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
574	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
627	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
663	Pos	Neg	Neg	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
668	Pos	Neg	Uns	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
683	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Inc	Pos-C	Uns	Inc	Pos-C	Pos-A
685	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Inc	Pos-C	Pos-A
691	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
710	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Inc	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
715	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Inc	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
725	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
729	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Inc	Pos-A	Pos-C	Pos	Pos-C	Neg	Pos	Pos-C	Pos-A
743	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
745	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
775	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
782	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
924	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
934	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
941	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
962	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A
974	Pos	Neg	Pos	Pos-C	Neg	Pos-C	Pos	Pos-A	Pos-C	Pos	Pos-C	Neg	Neg	Pos-C	Pos-A



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Histopathology and immunohistochemistry interpretation EQA 2024

Distribution October 2024

Slide review form

Observer ID:	
Date of EQA round:	
Case number:	
Original observer result:	
Intended (gold standard) result:	
Date of review:	
Further observer comments following review:	